Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EPS (Weighted Average and Diluted) (2021 - 2025)

Tango Therapeutics (TNGX) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.33 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 1.22% year-over-year to -$0.33; the TTM value through Dec 2025 reached -$0.33, up 71.93%, while the annual FY2025 figure was -$0.87, 26.89% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.33 in Q4 2025 per TNGX's latest filing, up from -$0.35 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.02 in Q2 2021 and bottomed at -$0.36 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.29, with a median of -$0.31 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 1551.16% in 2022, then soared 30.3% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.26 in 2021, then fell by 26.92% to -$0.33 in 2022, then rose by 9.09% to -$0.3 in 2023, then decreased by 10.0% to -$0.33 in 2024, then dropped by 1.22% to -$0.33 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.33 in Q4 2025, -$0.35 in Q2 2025, and -$0.36 in Q1 2025.